Exactly… Creatine and Taurine next to the Kuerig machine… in my morning coffee everyday.
And on gym evenings… every other day… I make a short coffee with creatine before heading over to the gym… perfect workout energy drink.
2 Likes
I enjoyed this podcast. The guest is a neuroscientist who (part-time) does work for Formula 1 teams to help optimize the performance of their drivers. Interesting in part because they have very good control over all aspects of the driver’s regimen, from supplements to their entire diet (they all have personal chefs, so easy to know exactly what they are eating). But, not too much new here for you if you’ve been following the science here already…
Neuroscientist Reveals What’s Actually Working for Brain Longevity (with Dr. Tommy Wood)
I. Executive Summary
This transcript analyzes the clinical frameworks of Dr. Tommy Wood regarding cognitive longevity, neuroplasticity, and high-performance biomarker optimization. The core thesis argues that the adult brain is not a structurally static organ doomed to inexorable decline, but a highly plastic tissue that dynamically maps its physical structure to environmental demands. Wood introduces a tripartite “3S Model” (Stimulus, Supply, Support) as the biological scaffolding for neurogenesis and synaptic remodeling.
The primary driver of structural neural adaptation is friction—specifically, dopaminergic error signals (mismatch negativity) and systemic arousal (catecholamine elevation) induced by novel, high-intensity cognitive and physical tasks. Without a precipitating stimulus, exogenous efforts to increase neuroplasticity—such as Transcranial Magnetic Stimulation (TMS) or psilocybin—lack functional utility and risk maladaptive network reinforcement.
Regarding “Supply” and “Support,” the transcript dissects critical translational gaps in biomarker management. Notably, it addresses the synergy required in nutrient supply, highlighting that isolated biomarker optimization often fails. For example, B-vitamin interventions to halt brain atrophy are biologically inert without a concurrent, optimal Omega-3 index. Furthermore, the analysis confronts the significant clinical risk of hyper-lipidemic ketogenic diets. The initial, though highly debated and retracted, data from the Keto CTA trial suggests that metabolically healthy individuals can still experience rapid, heterogeneous atherosclerotic plaque progression when driving extreme elevations in ApoB and LDL, debunking the absolute safety of the “Lean Mass Hyper-Responder” phenotype. The overarching clinical imperative is that cognitive aging and performance optimization demand structured, multi-system physiological management rather than reliance on isolated nutraceuticals or untested pharmaceutical longevity protocols.
II. Insight Bullets
- Neurogenesis is anatomically restricted in adults, but macro-level neuroplasticity—encompassing synaptic pruning, myelination, and astrocytic remodeling—remains active through the eighth decade.
- The Yerkes-Dodson curve dictates neuroplasticity: structural adaptation requires an optimal arousal state, driven by moderate aerobic exertion, brief cold exposure (60-70°F), or hyper-ventilation prior to a learning bout.
- Mismatch negativity (the discrepancy between predicted and actual outcomes) causes a transient pause in dopaminergic firing; this error signal is a mandatory trigger for neural network updating.
- Age-specific incidence of dementia has been steadily declining since WWII, primarily driven by improved population-level cardiovascular disease management and early-life nutritional density.
- Ketogenic diet-induced hyperlipidemia (elevated ApoB/LDL) carries a documented risk of driving soft plaque progression even in metabolically healthy phenotypes, necessitating aggressive coronary CTA surveillance.
- Supra-physiological zinc supplementation—frequently deployed for immune support—competitively inhibits enteral copper absorption, causing clinical hypocupremia and secondary neutropenia.
- Chronically elevated serum Vitamin B6 is endemic in high-performance athletes due to sports supplement overconsumption, increasing the risk for peripheral neuropathy.
- Processing speed cognitive training (e.g., double-decision tasks) increases cholinergic signaling in the forebrain, yielding statistically significant dementia risk reduction up to 20 years post-intervention.
- Homocysteine-lowering protocols via B-vitamin complex supplementation fail to prevent brain atrophy unless the patient’s concurrent Omega-3 index is >6-8%.
- High-Intensity Interval Training (HIIT) generates systemic lactate that crosses the blood-brain barrier to upregulate localized production of Brain-Derived Neurotrophic Factor (BDNF) in the hippocampus.
- Resistance training specifically preserves white matter volume and executive function, mediated via mechanical overload triggering systemic IGF-1 release.
- Resting Heart Rate Variability (HRV) is an inferior predictor of next-day athletic performance; it reflects the systemic physiological cost of prior exertion rather than immediate functional readiness.
- Indoor PM2.5 air pollution drives neuroinflammation and endothelial dysfunction; sustained use of HEPA filtration yields measurable, non-pharmacological reductions in systemic blood pressure.
- Unimodal steady-state aerobic exercise provides inferior cognitive adaptations compared to coordinative exercise (e.g., racket sports), which force simultaneous metabolic output and spatial-temporal processing.
- Routine hemoglobin screening is necessary to detect occult Obstructive Sleep Apnea (OSA), which frequently presents as secondary polycythemia (high hemoglobin) in athletes and aging males.
- Exogenous ketone administration (MCTs or acetoacetate) can bypass impaired cerebral glucose hypometabolism in Mild Cognitive Impairment (MCI), but efficacy in cognitively normal individuals remains unverified.
- Menopausal hormone therapy effectively mitigates vasomotor symptoms—which independently degrade cognition via sleep fragmentation—but evidence for direct, long-term dementia risk reduction in asymptomatic women is conflicting.
- Glymphatic clearance of amyloid-beta and localized adenosine degradation are strictly dependent on uninterrupted sleep architecture; sleep fragmentation mechanically halts this cerebral washout.
- TMS (Transcranial Magnetic Stimulation) functions as a “sledgehammer” that indiscriminately opens neuroplastic windows; without immediate targeted skill application, the induced plasticity is squandered.
III. Adversarial Claims & Evidence Table
| Claim from Video | Speaker’s Evidence | Scientific Reality (Current Data) | Evidence Grade | Verdict |
|---|---|---|---|---|
| High zinc supplementation lowers copper and neutrophils. | Clinical biomarker monitoring in F1 athletes. | High enteric zinc upregulates intestinal metallothionein, which preferentially binds and traps dietary copper, leading to sloughing and systemic deficiency. Wessels et al., 2021 | Level A | Strong Support |
| B-vitamins only prevent brain atrophy if Omega-3 status is optimal. | VITACOG trial (Oxford). | Subgroup analyses of RCTs confirm homocysteine-lowering therapy only slows cerebral atrophy and cognitive decline when baseline plasma omega-3 fatty acid concentrations are high. Oulhaj et al., 2016 | Level B | Strong Support |
| HIIT (Norwegian 4x4) increases hippocampal volume via lactate. | 6-month randomized exercise trial. | HIIT significantly increases serum lactate, which crosses the BBB via monocarboxylate transporters to stimulate local hippocampal BDNF expression. Muller et al., 2020 | Level B | Plausible |
| PDE5 inhibitors (Viagra) lower dementia risk. | UK/US observational database studies. | Large cohort studies show associations between sildenafil use and lower Alzheimer’s risk, but are heavily confounded by the “healthy user effect” (active sex life, better baseline vascular health). Adesoyan et al., 2024 | Level C | Speculative |
| Processing speed brain training reduces dementia risk. | ACTIVE study (20-year follow-up). | The ACTIVE RCT demonstrated that speed-of-processing training, but not memory or reasoning training, resulted in a significant 29% reduction in dementia risk after 10+ years. Edwards et al., 2017 | Level B | Strong Support |
| Ketogenic diet causes rapid plaque progression in healthy individuals. | Retracted/Preliminary Keto CTA trial. | Mechanistically, sustained extreme ApoB elevation (>200 mg/dL) drives LDL particle intimal penetration, risking atherogenesis irrespective of insulin sensitivity. Final CTA human data is still pending publication. Source unverified in live search (Data embargoed/retracted). | Level C | Safety Warning |
| Cocoa flavanols improve cognition in poor diets. | COSMOS-Web trial. | Dietary flavanol replenishment in older adults with low baseline diet quality significantly improves dentate gyrus-mediated memory. Brickman et al., 2023 | Level B | Strong Support |
| Indoor air filters reduce blood pressure. | JAMA environmental intervention study. | RCTs confirm that reducing indoor PM2.5 via portable HEPA purifiers significantly lowers systolic blood pressure and systemic inflammatory markers. Brook et al., 2020 | Level B | Strong Support |
IV. Actionable Protocol (Prioritized)
High Confidence Tier
- Synergistic Neuro-Nutrient Titration: Do not supplement B-vitamins for homocysteine reduction in isolation. Target a combined plasma Omega-3 Index of >8% (via EPA/DHA) and a serum Homocysteine level of <11 µmol/L to functionally halt accelerated brain atrophy.
- Processing Speed Preservation: Deploy targeted cognitive speed-of-processing tasks (e.g., visual double-decision training) rather than passive puzzles (crosswords). This specifically maintains cholinergic forebrain signaling pathways that rapidly decay post-age 60.
- Vascular Defense via HEPA: Install PM2.5-rated air filtration in primary sleeping and working zones. Airborne particulate matter drives endothelial dysfunction, blunting the neurovascular coupling required for localized cerebral blood flow during cognitive exertion.
Experimental Tier
- Arousal-Primed Skill Acquisition: Spike systemic catecholamines prior to deep cognitive work to widen the neuroplastic window. Utilize 20-30 minutes of moderate zone 2 cardio, or brief cold-water exposure (60-70°F), immediately preceding the learning bout.
- Coordinative Aerobic Loading: Transition 30% of weekly unimodal cardio (jogging/cycling) to coordinative sports (e.g., squash, martial arts). The simultaneous metabolic and spatial-temporal processing demands yield superior structural hippocampal adaptations compared to rote exertion.
Red Flag Zone
- Hyper-Lipidemic Ketogenic Diets: Safety Data Absent. The presumption that high ApoB and LDL are biologically benign in the presence of high insulin sensitivity (the “Lean Mass Hyper-Responder” hypothesis) is a severe translational gap. Proceeding with unmanaged ApoB >150 mg/dL requires immediate baseline and annual Coronary CTA tracking.
- Uncycled Zinc Supplementation: Continuous, high-dose zinc prophylaxis for respiratory immunity will induce severe hypocupremia and neutropenia. Limit high-dose zinc acetate strictly to the 48-hour prodromal phase of upper respiratory tract infections.
- Undirected Neuroplastic Agonists: Initiating TMS, psilocybin, or intensive breathwork protocols without immediate, rigorous integration (structured skill learning or clinical therapy) wastes the neuroplastic window and risks cementing maladaptive ruminative networks.
V. Technical Mechanism Breakdown
- Neurovascular Coupling & Endothelial Health: Cognitive exertion demands localized metabolic substrates. Active neural networks trigger adjacent astrocytes to release vasoactive signaling molecules (e.g., arachidonic acid metabolites), causing focal capillary dilation. Systemic atherosclerosis or endothelial dysfunction (driven by PM2.5 exposure or ApoB accumulation) physically blunts this vasoreactivity, starving the activated cortical regions of oxygen and glucose and accelerating neuronal apoptosis.
- The Lactate-BDNF Axis: During HIIT, anaerobic glycolysis produces systemic lactate. Circulating lactate crosses the blood-brain barrier via Monocarboxylate Transporters (MCTs). Within the CNS, lactate acts not only as an energy substrate for neurons but as a signaling molecule that modulates NMDA receptor activity and upregulates the expression of the BDNF gene, stimulating structural growth in the dentate gyrus of the hippocampus.
- IGF-1 & White Matter Myelination: Resistance training subjects skeletal muscle to mechanical overload, stimulating local mechanotransduction pathways and hepatic secretion of Insulin-like Growth Factor 1 (IGF-1). Systemic IGF-1 penetrates the central nervous system, where it acts as an obligate trophic factor for oligodendrocyte survival. Oligodendrocytes are responsible for synthesizing myelin sheaths; thus, IGF-1 preserves white matter tract integrity and action potential propagation velocity (executive function).
- Competitive Enteral Mineral Inhibition: Zinc and copper utilize identical transcellular transport mechanisms in the intestinal lumen. High exogenous zinc boluses artificially upregulate the expression of metallothionein, an intracellular binding protein within enterocytes. Metallothionein has a higher binding affinity for copper than for zinc. It traps dietary copper within the enterocyte, which is eventually sloughed off and excreted in feces, inducing systemic hypocupremia and a subsequent failure in neutrophil maturation in the bone marrow.
- Mismatch Negativity (MMN) & Synaptic Pruning: Adult neuroplasticity is heavily gated by dopaminergic tone. When an individual attempts a novel task and fails, the disparity between the predicted outcome and the actual result triggers “mismatch negativity.” This manifests as a transient suppression of phasic dopamine release in the striatum and prefrontal cortex. This error signal chemically tags the active synapses for pruning or long-term potentiation (LTP), physically rewiring the network to increase future predictive accuracy.
4 Likes
Note, Dr. Tommy Wood also has his own podcast…
Hosted by Drs. Tommy Wood and Josh Turknett, the Better Brain Fitness podcast explores the frontiers of how to keep our brain healthy and fit, so that we can perform at our best and do the things we love for as long as possible.
https://www.brainjo.academy/the-better-brain-fitness-podcast/
and his new book: Amazon.com: The Stimulated Mind: Future-Proof Your Brain from Dementia and Stay Sharp at Any Age: 9780593797815: Wood, Dr. Tommy: Books
And if you want to go deeper into neuroscience podcasts… I found this:
3 Likes
I had AI speculate and compare 6 mg Rapamycin + grapfruit Juice vs 6 mg rapamycin plus 1000 mg berberine daily. This is what I got.
Grapefruit Juice + 6 mg Rapamycin
This is well-studied in transplant literature:
- Mechanism: Irreversible destruction of intestinal CYP3A4 + P-gp inhibition
- AUC increase: ~3.5× baseline (some studies: 2.9–4.3×)
- Cmax increase: ~2.5–3.5×
- Tmax: Slightly earlier (faster absorption due to less gut-wall metabolism)
- Effective dose equivalent: 6 mg + grapefruit ≈ roughly ~18–21 mg rapamycin alone
- Duration of effect: Persists 24–72 hrs after the juice (enzyme destroyed)
- Predictability: Relatively consistent effect — furanocoumarin content of juice varies somewhat, but the irreversible mechanism makes it fairly reproducible
One famous small study in transplant patients used deliberate grapefruit co-administration to stretch rapamycin doses and save costs — the effect was that reliable.
Berberine 1000 mg/day + 6 mg Rapamycin
This is less directly studied in humans for sirolimus specifically, but can be estimated from its known PK profile:
- Mechanism: Reversible CYP3A4 inhibition + P-gp inhibition + possible CYP2C19 effects
- AUC increase: Estimated ~1.5–2.5× (moderate inhibitor classification)
- Cmax increase: ~1.4–2×
- Tmax: Modest shift, possibly slightly earlier
- Effective dose equivalent: 6 mg + berberine ≈ roughly ~9–15 mg rapamycin alone
- Duration of effect: Dissipates as berberine clears (~3–5 hrs half-life), but at steady-state 1000 mg/day, inhibition is maintained chronically
- Predictability: More variable — depends on berberine absorption (itself poorly bioavailable, ~5%), gut microbiome conversion, and individual CYP3A4 expression
Side-by-Side Comparison
| Parameter | Rapamycin Alone | + Grapefruit Juice | + Berberine 1000 mg/day |
|---|---|---|---|
| Bioavailability | ~15% | ~45–60% | ~25–35% (est.) |
| AUC fold-increase | 1× | ~3–4× | ~1.5–2.5× |
| Cmax fold-increase | 1× | ~2.5–3.5× | ~1.5–2× |
| Tmax | 1–3 hr | Slightly earlier | Modest change |
| Effect duration | — | 24–72 hrs post-juice | Continuous at steady state |
| P-gp inhibition | — | Yes | Yes |
| Reversibility | — | No (enzyme destroyed) | Yes |
| Human PK data quality | High | High | Low–moderate (indirect) |
6 Likes
3HAA: The Longevity Molecule You’ve Never Heard Of
Executive Summary
The core thesis of this research identifies 3-hydroxyanthranilic acid (3HAA), a downstream metabolite of the tryptophan/kynurenine pathway, as a potent endogenous longevity factor. Traditionally, research in this pathway focused on kynurenine’s role in inflammation and its eventual conversion to NAD+. However, Kaeberlein’s data suggests that the intermediate metabolite 3HAA itself is sufficient to extend lifespan, potentially independent of NAD+ synthesis.
In C. elegans, genetic knockdown of the enzyme 3-hydroxyanthranilic acid dioxygenase (HAAO)—which degrades 3HAA—results in a ~30% lifespan extension. This effect is mirrored by direct supplementation of 3HAA. In mice, both genetic HAAO knockout and late-life 3HAA dietary supplementation (starting at 18–27 months) resulted in reproducible lifespan extension (~15% in knockouts). Mechanistically, 3HAA appears to act as a metabolic signaling molecule that triggers a robust, multi-modal stress response. Key pathways involved include NRF2/SKN-1 (oxidative stress resistance), DAF-16/FOXO, and hypoxia-inducible factors.
Despite these promising results, significant translational hurdles exist. Historically, 3HAA was erroneously labeled a carcinogen due to flawed 1960s-era rat bladder studies involving direct bolus implantation. While it has recently been removed from major carcinogen lists, recent independent data (2026) suggests potential detrimental effects on bone mineral density, indicating a complex pleiotropic profile. Furthermore, as an endogenous molecule, 3HAA lacks a traditional patent-protected path to FDA approval, slowing commercial development. The current evidence is strictly pre-clinical (Level D), and human application remains speculative and potentially hazardous without further safety profiling regarding bone health and long-term systemic effects.
II. Insight Bullets
- Novel Longevity Target: 3HAA is identified as a “longevity molecule” within the kynurenine pathway, separate from the more famous NAD+ precursors.
- Enzyme Inhibition: Knocking down or inhibiting the enzyme HAAO (3-hydroxyanthranilic acid dioxygenase) increases 3HAA levels and extends life.
- Worm Lifespan: C. elegans show a 25–30% increase in lifespan when 3HAA levels reach millimolar concentrations in the intestine.
- Mouse Lifespan: HAAO knockout mice show a ~15% lifespan extension, though they exhibit a “slow-growth” phenotype in early life.
- Late-Life Intervention: Supplementing 3HAA in mice as late as 27 months (extremely old) still yields significant survival benefits.
- Sex Dimorphism: Lifespan benefits in mice vary by sex; dietary 3HAA favors males, while genetic knockout favors females.
- NAD+ Independence: Longevity effects persist even when NAD+ production through the kynurenine pathway is blocked, suggesting 3HAA works via independent signaling.
- Intestinal Health: 3HAA appears to improve gut barrier function and host-microbiome interactions in model organisms.
- Pathogen Resistance: Elevated 3HAA confers resistance to specific bacteria like Pseudomonas.
- Hormetic Stress Response: 3HAA activates a “master” stress response, including NRF2 (antioxidant), FOXO (metabolic), and hypoxic pathways.
- Historical Hype/Fear: 1960s studies misidentified 3HAA as a bladder carcinogen; recent re-evaluation led to its removal from many carcinogen lists.
- The FMO2 Link: 3HAA may converge with FMO2 (Flavin-containing monooxygenase 2), a known “funnel point” for multiple longevity pathways in worms.
- Translational Gap: No human clinical trials exist; the transition from millimolar worm concentrations to human doses is undefined.
- Commercial Disincentives: As an unpatentable endogenous molecule, 3HAA lacks the financial backing required for expensive human trials.
- Pharmacological Challenge: Small molecule inhibitors of HAAO currently exist but are non-specific and can generate reactive oxygen species (ROS) as a byproduct.
III. Adversarial Claims & Evidence Table
| Claim from Video | Speaker’s Evidence | Scientific Reality (Current Data) | Evidence Grade | Verdict |
|---|---|---|---|---|
| 3HAA extends mouse lifespan | Lab studies (HAAO KO and 3HAA diet) | Van Rompay et al., 2023 confirms 3HAA extends lifespan in worms and mice. | D | Strong Support (Pre-clinical) |
| 3HAA is a carcinogen | 1960s rat bladder studies | IARC/GBD Data 2022-2026 suggests smoking/glucose are primary drivers; 3HAA generally removed from carcinogen lists. | E | Unsupported (Historical) |
| 3HAA activates NRF2 | Worm stress response assays | Sykiotis et al., 2011 and 2023 3HAA paper confirm NRF2/SKN-1 activation. | D | Strong Support (Pre-clinical) |
| 3HAA is safe for humans | (Inferred from endogenous status) | PubMed 41580082 (2026) states 3HAA impairs osteoblast differentiation and bone mass in mice. | D | Safety Warning (Bone Risk) |
| NAD+ is not the primary mechanism | HOW knockdown blocks NAD+ but extends life | Source unverified in human clinical RCTs; confirmed in worms/mice in Van Rompay et al., 2023. | D | Plausible (Pre-clinical) |
IV. Actionable Protocol (Prioritized)
1. High Confidence Tier (Level A/B)
- None Identified: There are currently zero Human Meta-analyses or RCTs supporting the use of 3HAA or HAAO inhibitors for longevity or healthspan.
2. Experimental Tier (Level C/D)
- Tryptophan Metabolism Monitoring: Clinicians may monitor kynurenine/tryptophan ratios as markers of systemic inflammation, though the specific 3HAA target remains purely experimental.
- NRF2 Activation (Indirect): Using established Level B NRF2 activators (e.g., sulforaphane, exercise) may mimic the downstream stress-response benefits of 3HAA without the unquantified risks of the metabolite itself.
3. Red Flag Zone
- Self-Supplementation: DO NOT attempt 3HAA supplementation. High-dose exposure is linked to bone density loss and DNA damage in mesenchymal stem cells [PubMed 41580082].
- Safety Data Absent: There is a total lack of human safety data regarding long-term elevation of 3HAA, particularly concerning its potential to induce senescence in specific cell types.
V. Technical Mechanism Breakdown
The biological efficacy of 3HAA revolves around Metabolic Reprogramming and Hormetic Stress Signaling:
- HAAO Inhibition/3HAA Accumulation: The enzyme HAAO (3-hydroxyanthranilic acid dioxygenase) normally converts 3HAA into quinolinic acid, a precursor to NAD+. Blocking this enzyme forces an accumulation of 3HAA.
- NRF2/SKN-1 Activation: 3HAA appears to act as a mild pro-oxidant or signaling molecule that stabilizes NRF2(SKN-1 in worms). This triggers the transcription of a suite of antioxidant and phase II detoxification genes.
- FMO2 Interaction: 3HAA levels may be sensed by FMO2 (Flavin-containing monooxygenase 2). FMO2 acts as a metabolic node that consumes NADPH to oxidize various substrates, effectively “rewiring” the cell’s redox state to favor longevity over rapid growth.
- Hypoxia Mimicry: Elevated 3HAA partially activates HIF-1 (Hypoxia-Inducible Factor 1) signaling, which improves mitochondrial efficiency and activates proteostasis mechanisms, similar to the effects of caloric restriction.
- Pleiotropic Antagonism: While 3HAA promotes longevity in post-mitotic tissues (like worm intestines), it may be toxic to regenerative tissues (like bone-forming osteoblasts) by inducing DNA damage and cellular senescence via the Aryl Hydrocarbon Receptor (AhR) pathway.
1 Like
Actionable Intelligence
1. The Translational Protocol (Rigorous Extrapolation)
-
Human Equivalent Dose (HED):
- Animal Data: The primary lifespan-extending dose in mice cited by Kaeberlein and confirmed in literature is 200 mg/kg (administered I.P. or via enriched diet).
-
Calculation: Using the FDA’s Body Surface Area (BSA) normalization:
- Formula: HED=Animal Dose (mg/kg)×(Human KmAnimal Km)
- Parameters: Mouse Km=3; Human Km=37.
- Math: 200 mg/kg×(3/37)≈16.2 mg/kg.
- Result: For a 70 kg adult, the theoretical HED is 1,134 mg/day.
-
Pharmacokinetics (PK/PD):
- Bioavailability: Low to moderate. 3HAA is highly redox-active and susceptible to autoxidation. Oral delivery efficacy is unquantified in humans; mice studies often bypass this via I.P. injection.
- Half-Life: Extremely short. In plasma, 3HAA is rapidly metabolized or degraded. In C. elegans, it accumulates in lysosome-related organelles, but in mammals, it is quickly cleared or converted to quinolinic acid/NAD+ unless HAAO is inhibited.
-
Safety & Toxicity:
- NOAEL/LD50: Safety Data Absent for humans. Mouse LD50 for acute I.P. injection is not standardized in longevity literature, but chronic 200 mg/kg was tolerated without overt lethality.
- Liver/Kidney: Chronic HAAO inhibition in mice (elevating 3HAA) improved liver pathology scores and decreased atherosclerosis markers. However, 3HAA is a known precursor to quinolinic acid, a potent neurotoxin.
- Bone Toxicity: Critical Signal. Recent 2026 data indicates 3HAA impairs osteoblast differentiation and reduces bone mineral density. This is a primary barrier to human translation.
2. Biomarker Verification
- Target Engagement: Reduction in hepatic SREBP-2 mRNA and nuclear translocation.
- Systemic Markers: Elevated plasma 3HAA:Anthranilic Acid (AA) ratio.
- Downstream Effectors: Induction of Heme Oxygenase-1 (HO-1) and NQO1 in peripheral blood mononuclear cells (PBMCs), signaling NRF2 activation.
3. Feasibility & ROI
- Sourcing: Currently a Research Chemical only. Not available as a GRAS (Generally Recognized as Safe) supplement or Rx.
- Cost: Sigma-Aldrich pricing is approximately $1,390 per 1 gram.
- ROI Analysis: At a theoretical HED of 1.1g/day, the monthly cost would exceed $40,000. Even bulk chemical sourcing would likely remain prohibitively expensive ($500+/month) with no human efficacy data to justify the spend.
Part 5: The Strategic FAQ
- Q: If 3HAA is a precursor to the neurotoxin quinolinic acid, why doesn’t supplementation cause neurodegeneration?
- A: Longevity benefits rely on the metabolite itself or the inhibition of its breakdown. If HAAO is inhibited, 3HAA accumulates and quinolinic acid production actually decreases, potentially offering neuroprotection.
- Q: How does 3HAA-induced bone loss compare to the lifespan gains?
- A: This is a classic “evolutionary trade-off.” 3HAA may extend life by prioritizing cell maintenance (NRF2) at the expense of skeletal remodeling. In humans, this could manifest as severe osteoporosis.
- Q: Can we achieve the same effect by simply taking NRF2 activators like Sulforaphane?
- A: Likely not. 3HAA appears to act through a unique convergence of NRF2, FOXO, and FMO2. It is a multi-modal “metabolic master-switch” rather than a single-pathway activator.
- Q: Is the sex-dimorphic response in mice (Males favoring diet, Females favoring genetics) relevant to humans?
- A: Unknown, but highly probable given kynurenine pathway interactions with estrogen signaling.
- Q: Why start treatment at 18–24 months in mice? Is there a “window of opportunity”?
- A: Kaeberlein suggests 3HAA works best as a “rescue” molecule for age-related stress. Starting too early might interfere with the “slow-growth” phenotype seen in genetic knockouts.
- Q: Does 3HAA supplementation affect the gut microbiome directly?
- A: Yes. It provides resistance to pathogens like Pseudomonas and alters host-microbe signaling to improve intestinal barrier integrity.
- Q: What is the risk of “pro-oxidant” damage if the dose is too high?
- A: 3HAA is redox-active. In the presence of certain metals, it can generate ROS, potentially causing the DNA damage seen in bone marrow cells.
- Q: Is there any evidence that 3HAA increases NAD+ levels significantly?
- A: Minimal. The longevity effect persists even when the NAD+ de novo pathway is blocked, suggesting the benefit is signaling-based, not fuel-based.
- Q: Could HAAO inhibitors be a better drug target than 3HAA itself?
- A: Theoretically, yes, but current inhibitors generate ROS during the inhibition process, making them currently “dirty” drugs.
- Q: Should a patient with a history of bladder cancer avoid 3HAA?
- A: Yes. Despite its removal from carcinogen lists, the historical data and 3HAA’s known ability to induce DNA damage in specific contexts warrant extreme caution in oncology-prone individuals.
Interaction Check (Common Longevity Stack):
- Rapamycin: Synergistic Risk. Both inhibit growth pathways. Combined use could exacerbate “slow-growth” or impaired wound healing.
- Metformin: Low Risk. Different mechanisms; 3HAA focuses on redox stress while Metformin focuses on AMPK/complex I.
- SGLT2 Inhibitors: High Risk. SGLT2i are linked to changes in bone mineral density; combining with 3HAA could accelerate skeletal fragility.
- Acarbose: Neutral/Positive. 3HAA improves gut health; Acarbose also modulates the microbiome. No known direct contraindication.
- 17-alpha Estradiol: Unknown. Potential interference due to sex-specific effects of the kynurenine pathway.
- PDE5 Inhibitors: No known interaction.
10 Likes
I have grown to have a lot of respect for Dr. Matt Kaeberlein. He helped me reduce my polyparma and supplement load for one thing, thus saving me a lot of money. I wish him well, and I hope he keeps contributing to the forum or shows where to follow his endeavors. I worked in an environment with many PhDs, and jealousy and infighting over promotion and recognition were common.
In a room full of PhDs. Most of them will think they are the smartest person in the room. So conflict is common.
"While he remained at Optispan, several high-profile incidents have created a pattern of friction with major institutions. The Dog Aging Project debacle is particularly important to note, as it not only strained his relationship with the NIH but also highlighted a core tension between rigorous science and the need for rapid funding—a tension at the heart of his current role.
Given this history, here are three plausible scenarios that could, in theory, lead him to leave Optispan. These are speculative and rooted in broader industry trends.
Scenario 1: Conflict with Investors
The most direct speculation points to a potential conflict with Optispan’s financial backers. He is a pure scientist who has drawn hard lines against hype and "pseudoscience", but investors typically demand rapid commercial returns. If the board pushed for marketing strategies or product claims he deemed scientifically unsound, a departure would be consistent with his record of resigning from organizations he feels are compromising integrity for gain.
Scenario 2: Fading Public Interest in Longevity
If you can’t sell the dream, you can’t sustain the startup. The longevity space saw a massive hype cycle peak around 2021-2023. While Kaeberlein has always been a voice of scientific sobriety in a field of hype, a general downturn in public and investor interest would put immense pressure on any for-profit company. If funding for healthspan optimization became scarce and the business model proved unsustainable, stepping down could be a strategic move to pivot before a collapse.
Scenario 3: Strategic Pivot Back to Research
Kaeberlein is a scientist first. He left a prestigious university position because he felt he could have a greater impact in the private sector. However, running a startup requires a different skillset than leading a lab. He might conclude that raising $50 million for the non-profit Dog Aging Institute is a more impactful legacy than building a commercial health technology platform. Stepping down as CEO could free him to focus entirely on that massive fundraising and research effort without the burden of a for-profit business.
What He Might Say (Discounting the Official Line)
Of course, it is way too early to determine the exact reasons for his departure; I am sure they will eventually come out.
As is wont to happen in nosy humans, I asked various AIs for a speculative analysis.
“No reason given, not even a sanitized one.”
“No longer at” is the phrasing of someone who was shown the door or walked out — not someone who orchestrated a graceful succession. A voluntary, planned handover usually reads “I’m transitioning to [role]” or “handing the reins to [name],” with the successor named. There’s no successor named. There’s no bridge.
The prompt instructs us to discount his stated reasons, so these are presented as the “official” explanations he would likely provide, not the “real” reasons.
- “To focus on the Dog Aging Project”: Given his public desperation to save the project, this would be the most logical and publicly acceptable explanation. The “real” reason might be Scenario 3—a belief that the for-profit model is not the right vehicle for fundamental geroscience research.
- “To pursue other opportunities”: This is the standard vague, non-answer answer. In his case, it could mask Scenario 1, a falling out with the board over the company’s strategic direction.
- “For personal reasons”: This could cover anything from burnout to a desire to spend more time on his own health protocols, but is also a credible smokescreen for Scenario 2, where the company is quietly struggling."
This is a surprise. But - and this is perhaps not a surprise - I have always been pretty reserved vs Optispan, and said so on these boards. In short, I didn’t think that, apart from Matt, the caliber of the other people involved - insofar as I could tell from interviews - was particularly stellar. In fact, I always thought they were pretty subpar. And from what I could gather about the program, anyone here - or any reasonably aware biohacker - really didn’t need it at all. Commonsensical and not particularly revelatory stuff for the price. Basically a waste of time - IMHO.
That said, maybe it’s all for the good, if Matt can focus more on science. I hope he strikes out and keeps a yt channel separate from Optispan to keep in touch with a broader audience, but otherwise, I see it mostly as a win. Of course, that’s just my uninformed opinion looking at it from the outside not privy to any inside info.
3 Likes
It was a shock. I hope Dr Kaeberlein lands on his feet quickly and continues to speak his mind. He is the only reliable truth teller in this area, which is no way to make a lot of money but I offer my thanks (for what that’s worth). I have modeled my limited supplement stack on his advice (plus some personal experience). Good luck!
3 Likes
Wow, I’m also surprised. And yes @CronosTempi, he was the only one related to that company I would trust with my health.
PS, I’m not referring to the side-kick seemingly nice young man who would co-host his podcast.
I will greatly miss his podcasts. I watched almost all of them and have nothing but respect for the guy.
3 Likes